Single booster dose with updated bivalent COVID-19 vaccine provides broad protection against COVID-19 including Omicron variant
On Jan. 11, 2023, the U.S. Food and Drug Administration reported that a single booster dose with an…
Paxlovid reduced serious risks from Omicron variants
On Jan. 10, 2023, the U.S. National Institutes of Health (NIH) reported that antiviral treatments can help reduce…
NIH launched Home Test to Treat, a pilot COVID-19 telehealth program
On Jan. 5, 2023, the National Institutes of Health, in collaboration with the Administration for Strategic Preparedness and…
Spanish, Italian and French Health Authorities expanded recommendations for use of Novavax COVID-19 vaccine
On Jan. 5, 2023, Novavax announced that Spain’s Public Health Commission, Italy’s Ministry of Health, and France’s Haute…
BioNTech and Fosun Pharma announced regulatory approval of mono- and bivalent COVID-19 vaccine COMIRNATYﾮ in individuals 12 years and older in Hong Kong
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
U.S. Department of Health and Human Services increased access to Tamiflu through the Strategic National Stockpile
On Dec. 21, 2022, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic…
Moderna finalized strategic partnership with UK government
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
FDA approved Roche’s Actemra for treatment of COVID-19 in hospitalised adults
On Dec. 21, 2022, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Actemraﾮ (tocilizumab)…
Study revealed that duration of exposure to COVID-19 plays major role in risk of catching the virus
On Dec. 20, 2022, the University of Oxford announced study results using data from 7 million people notified…
German Health Authority expanded recommendation for use of Novavax COVID-19 vaccine as a booster
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
Swiss and French health authorities expanded recommendations for use of Nuvaxovid COVID-19 vaccine as booster
On Dec. 11, 2022, Novavax announced that the Switzerland’s Federal Office of Public Health and Francees Haute Autorite…
Biotechnology | COVID-19 | FDA | Influenza | Vaccine
Pfizer and BioNTech received U.S. FDA Fast Track Designation for single-dose mRNA-based vaccine candidate against COVID-19 and influenza
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
COVID-19 vaccine from Washington University in St. Louis approved for use as booster in India
On Dec. 9, 2022, Washington University in St. Louis announced that it’s nasal COVID-19 vaccine technology had been…
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
Biotechnology | COVID-19 | FDA | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children
On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use…
Biotechnology | COVID-19 | Therapeutics | Vaccine | WHO
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
On Dec. 7, 2022, Novavax announced that Health Canada had approved a supplement to a New Drug Submission…
Hutchinson Cancer Center leads large-scale review of COVID-19 clinical trials that highlights multiple disparities
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
Novavax updated EUA listing for Novavax Nuvaxovid COVID-19 vaccine as pimary series in adolescents and as booster in adults
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
FDA authorized Lucira COVID-19 & flu point-of-care test
On Nov. 22, 2022, the U.S. Food and Drug Administration issued an Emergency Use Authorization for the Lucira…
Biotechnology | COVID-19 | Medicine | Vaccine
Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster demonstrating improved immune response against Omicron sublineages
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
Novavax Nuvaxovid COVID-19 vaccine received expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
U.S. pandemic death toll higher than in 20 peer countries
On Nov. 18, 2022, the Journal of the American Medical Association reported that the U.S. experienced high COVID-19…
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint of superiority against omicron variants
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
Pfizer and BioNTech received positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children in EU
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
University of Missouri study found Monkeypox mutations caused virus to spread rapidly, evade drugs and vaccines
On Nov. 9, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…